Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K,
Keywords: neuroendocrine tumors, PET, Al18F-NOTA-octreotide, 68Ga-DOTATATE, somatostatin receptor imaging,
Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,
Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,
Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Carlsen E
Authors: Carlsen E, Johnbeck C, Binderup T, Loft M, Pfeifer A,
Keywords: 64Cu-dotatate, neuroendocrine neoplasm, progression-free survival, overall survival,
Introduction: Neuroendocrine neoplasms of the appendix are common GEP-NEN tumors.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Konsek S, Kolasińska-Ćwikła A, Lewczuk A, Kidd M, Cichocki A,
Keywords: neuroendocrine neoplasm, appendiceal neuroendocrine neoplasm, somatostatin receptor scintigraphy,
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Bodei L
Authors: Bodei L, Kidd M, Severi S, Drozdov I, Nicolini S,